ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKAL
1
curation_datecohortage_minage_maxage_unitsnumber_subjectstissue_typetissue_type_term_idmethodresponse_componentis_modelresponse_behavior_typeresponse_behaviorcomparisonbaseline_time_eventtime_pointtime_point_unitsexposure_materialexposure_material_idexposure_processdisease_namedisease_stagepublication_reference_idpublication_datepublication_reference_urlsignature_sourcecommentscurator_comments
2
subjectcell_subset(will be added by processing script)pathogen
7
descriptive text on Dashboardcuration date YYYY-MM-DDcohort - any characteristics of the population(s) studied, plus whether the result was taken from a subgroup of the broader cohort testedage_min - age of youngest subject including both cases and controlsage_max - age of oldest subject including both case and controlsage unitsnumber of subjects - count of case plus control subjects used in the measurement.tissue typetissue (Cell Ontology)method - primary experimental method used to measure the responseresponse componentsignature was derived from a computational modelresponse behavior typeresponse behavior (direction, correlation type etc.)comparison (affected vs control, correlated variable, time vs baseline event etc.)baseline time eventtime point relative to baseline event at which response was measuredtime point unitsexposure material (NCBI pathogen name)exposure material (NCBI taxid)exposure process - method by which immune exposure  occurreddisease namedisease stage - reported disease stage(s) of affected subjectspublication reference (PMID)print publication date or posted date YYYY-MM-DDpublication URLsignature source - figure, table or text section comments and additional detailscurator comments
8
vocabulary, separatorYYYY-MM-DDfree textnumbernumberchoose from listnumberFree text. Multiple entries must be separated with a semicolonChoose from list or lookup Cell Ontology code. Multiple entries must be separated by a semicolon, e.g. CL:0000576 (monocyte); CL:0000235 (macrophage). Just the code is also acceptable, e.g. CL:0000576Choose from list. Only one entry expected. You can add new methods.Gene or protein symbols can be separted with commas or semicolons. Cell types or other names must be separated using semicolons.Y/NChoose from list. Only one entry allowed. Choose from list. Only one entry allowed. Add new behaviors if required.Free text. Use "vs" rather than a dash to separate comparison terms (A vs B). When a reported response behavior with identical response components has been observed across multiple comparisons, they may be combined in one row; separate individual comparison entries with semicolons (A vs C; B vs C).Free textNumber or free textChoose from list. Lowercase onlyfree textChoose from list or use format ncbi_taxid:2697049Choose from list. Enter new process if needed.free textfree textpmid:nnnnnnnn or nnnnnnnnYYYY-MM-DDThe URL only, not any associated display textFree text. Multiple entries allowed if neededFree text, limit of 250 charactersFree text, no limit
9
Additional information for curatorsDate curation completedAny characteristics of the population(s) studied, besides age. Example:
Hong Kong, Atlanta

Also report if the result was limited to a subgroup of the tested cohort, e.g.
- subjects suffering adverse events
- particular threshold levels of antibody titer level
- based on a receiving a particular treatment		Include both case/affected and control subjectsInclude both case/affected and control subjectshours, days, months, yearsOften differs by signature within a publication. If number of subjects for a particular signature is not clear in text, use total for cohort.As reported. The parent tissue of the response components. For cell-type results, the tissue is often PBMCs, but can also be a specific base cell type. For gene expression, the tissue might be a specific base cell typeCell Ontology IDs for tissues in column “tissue_type”. If there is no matching cell type in the pulldown list, the curator can try to look up a matching term in the Cell Ontology. If there is no appropriate Cell Ontology term, UBERON codes can also be used.The primary experimental method used to measure the response, e.g. RNA-seq, CyTOF, CITE-seq. The entities whose response is being measured. Please copy symbols and names exactly as reported in the publication - except spell out greek letters. For cell types, this includes all markers.
Examples for a signature with three cell types:
T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+
CD86+ myeloid dendritic cell (DC); CD86+ monocyte		Were the response components chosen using a classification or other model-building strategy?The type of change being measured, e.g. gene expression, cell-type frequency.Common values in the pulldown list:
- up, down
- positively correlated, negatively correlated, correlated
- positively predictive, negatively predictive, predictive		Comparisons are typically between two groups, or may reflect a correlation of the response component with some other measured variable. Only report significant results. Examples:
- severe COVID-19 cases vs healthy
- moderate COVID-19 cases vs healthy; severe COVID-19 cases vs healthy
- interferon-stimulated genes in COVID-19 vs healthy
- bacterial DNA levels across COVID-19 and healthy subjects
Include time comparison if relevant, e.g. 7d vs 0d, where the times are relative to the baseline reference event time (0d). Times before baseline event can be entered as negative numbers, e.g. days before vaccination (7d vs -1d).
**Please be concise.**		The reference event from which the time of the experimental response is measured, e.g. hospital admission, onset of symptomsTime point when response was measured, e.g. “7”, “various”, “0 to 8”days, months etc.Enter the pathogen underlying the immune exposure as reported in the publication or use the NCBI Taxonomy term nameNCBI Taxonomy ID of pathogen causing diseaseMethod by which exposure to pathogen occurredE.g. COVID-19Reported disease stage(s) of affected subjects in all comparisons entered in row (not including control subjects). We will not attempt to match these directly with the comparisons. Examples include moderate, severe, ICU etc. Pooled can also be added.
Enter the PMID for the article curated, using format pmid:id,such as pmid:32788292, or just the id number, e.g. 32788292Partial dates are OK, e.g. YYYY-MMURL of the article curated. Please use PubMed if availableFigure, table number etc. where the signature was found, as given in the source listed in the publication_reference_url. Multiple entries allowed, i.e. if a result is drawn both from a primary and a supplemental sourceDetails clarifying any aspect of the signature not captured in other fields. Will appear in DashboardQuestions or notes for further examination from curator. Will not appear in Dashboard
10
2023-10-17Critically ill adult patients with severe COVID-19 admitted to Pediatric ICU, with or without secondary infection (Paris, France)4766yearsn = 29
No secondary infection n = 17
Secondary infection n = 12
myeloid dendritic cellCL:0000782 (myeloid dendritic cell)flow cytometryMonocytes (CD19-, CD14+, CD15-);
Monocyte myeloid-derived supressor cels (CD11b+ HLA-DR-);
Monocytic human leukocyte antigen-DR (mHLA-DR);
Ncell-type frequencypositively correlatedsevere COVID-19, singular infection event (n = 17) vs secondary infection (n = 12)ICU AdmissionvariousdaysSevere acute respiratory syndrome coronavirus 2
ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2)occurrence of infectious diseaseCOVID-19severe, ICUpmid:342599422021-07-01https://pubmed.ncbi.nlm.nih.gov/34259942/Figure 3; Figure 4; Tabe 2"No biologic markers but NK cells count, monocytes count and M-MDSC to total monocytes ratio significantly differed between both groups.";
"identified a third cluster of patients, with persistently high mHLA-DR, suggestive of protracted monocyte activation phenotype";
"Myeloid phenotypes of critically ill COVID-19 patients may be associated with development of secondary infection, 28- and 60-day mortality" ; "hyperactivated monocyte/macrophage is significantly associated with mortality, whereas persistent immunodepression is associated with secondary infection occurrence compared to transient immunodepression"
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104